Amanda Lovold, DO
Family Medicine · St Cloud, MNNPI 1821252800
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $385,840 of the $386,610 with a category attached, or 99.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 87.8% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $1895.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$339K
- Shire North American Group Inc$47K
- Novo Nordisk$20
What the payments were for
- Consulting fees$385,840100%
- Travel & lodging$7500%
- Food & beverage$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 179 | $339,270 |
| Shire North American Group Inc | 24 | $47,320 |
| Novo Nordisk | 1 | $20 |
How this compares
$386,610 in reported general payments places this provider in the 95th percentile of 1,162 family medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 56 | $72,828 |
| OzempicSemaglutide | 30 | $27,885 |
| JardianceEmpagliflozin | 20 | $26,596 |
| EliquisApixaban | 18 | $24,903 |
| XareltoRivaroxaban | 18 | $22,074 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,361 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,690 |
| Atorvastatin Calcium | 498 | $6,581 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $6,541 |
| Losartan Potassium | 320 | $4,398 |
| Omeprazole | 267 | $3,773 |
| SynthroidLevothyroxine Sodium | 38 | $3,540 |
| Levothyroxine Sodium | 230 | $3,318 |
| Metoprolol Succinate | 160 | $3,314 |
| Gabapentin | 120 | $2,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $20 | $27,88530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 family medicine providers in Minnesota.
Other family medicine in St Cloud
- Robert MarshMinnetonka$300K
- Taylor MertzMoorhead$176K
- Justin YoungTracy$93K
- Gerard SpoelhofDuluth$75K
- Martha MasciopintoCottage Grove$50K
- Glenn DetlefsenRosemount$39K
- Amy GilbertSaint Paul$27K
- Kevin PetersonMinneapolis$25K
- Joseph McGrathWabasha$19K
- Jay AllenDuluth$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.